An observational study in Diabetes Mellitus, Diabetes Complications and Diabetic Peripheral Neuropathy, sponsored by Centre Hospitalier Universitaire de Nīmes. Recruiting at 1 site in France. Per ClinicalTrials.gov, last updated 2026-11-13.
Sponsored by Centre Hospitalier Universitaire de Nīmes · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Diabetic Foot by Centre Hospitalier Universitaire de Nīmes — 3 open to participants now, 3 under way, none of them phase 3. Diabetic Foot · Centre Hospitalier Universitaire de Nīmes.
Among the 10 studies in Diabetic Foot by Centre Hospitalier Universitaire de Nīmes, this one is one of 2 that started in 2026, is one of 6 observational ones, and was the 10th registered.
1,079 studies on the registry are indexed under Diabetic Foot; 221 are open to participants now.
Browse Diabetic Foot studies →3 of the 10 studies in Diabetic Foot by Centre Hospitalier Universitaire de Nīmes are open now, in 1 country. Recruiting first, the newest first:
Centre Hospitalier Universitaire de Nīmes · Sites in France
Ages 18+
Centre Hospitalier Universitaire de Nīmes · Sites in France
Ages 18+
By country, each count listing its studies:
Of the 139 Diabetic Foot studies recruiting now, 98 (71%) set no upper age limit and 12 (9%) stop at 75 or younger; 5 take children under 18; 11 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2010; this study’s year is marked. 2 started in 2026.
This study's planned enrollment of 43 is below the median of 100 across 191 observational studies indexed under Diabetic Foot.
Median enrollment 47 across the 4 interventional studies, 190 across the 6 observational. Of the 7 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Centre Hospitalier Universitaire de Nīmes is the lead sponsor of 595 studies on the registry; 87 are open to participants now.
2 of the studies in Diabetic Foot by Centre Hospitalier Universitaire de Nīmes that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07391995Centre Hospitalier Universitaire de NīmesNew Diagnostic Tool (MinION) for Identifying Microorganisms in Foot Wounds of Patients Living With Diabetic Foot Osteomyelitis | 2027-06 |
| NCT05491577Centre Hospitalier Universitaire de NīmesFactors Associated With an Evolution in the Quality of Life of Diabetic Patients With Chronic, Wound-free Charcot Foot | 2027-07-22 |
Add all 2 to your calendar (.ics) → With an account.
Among the 10 studies in Diabetic Foot by Centre Hospitalier Universitaire de Nīmes, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Diabetic foot wound infections are predominantly polymicrobial. However, 'conventional' microbiological culture does not identify all the bacteria potentially involved in these infections and requires time, which can have a negative impact by delaying treatment and/or the prescription of appropriate antibiotic therapy.
Real-time metagenomics analysis using Oxford Nanopore Technologies' MinION technology has demonstrated sufficient power to identify virtually all microbial genomes in a given sample, providing additional information on their antibiotic resistance profile and in silico prediction of genes encoding virulence factors within than 4 hours. Based on these rapid results, a management protocol could be defined specifically for each patient with a view to personalised medicine.
The aim is to study the diversity of bacterial and fungal species identified using the MinION method and compare this diversity with the results obtained using conventional methods (routine culture) from bone biopsies taken from DFOM patients.
Diabetes mellitus is one of the most common diseases in the world. Among its complications, 34% of patients living with diabetes will develop foot ulcers during their lifetime. Once this lesion has developed due to triopathy (arteriopathy, neuropathy, immunopathy), over 50% of these wounds will become infected, leading to serious consequences: bone damage (60 to 80% of cases), amputation (20% of infected wounds), mortality (68% at 5 years) and morbidity. The additional costs associated with this condition exceed $850 billion worldwide, with $1 million spent every 30 seconds due to complications from these wounds in the US. Diabetic foot ulcers (DFUs) are therefore a major public health problem.
For infectious disease specialists, one of the main difficulties in treating infections in these wounds is distinguishing between bacterial colonization - a physiological process, and infection - a pathological process. Studies of the microbiota of foot wounds in diabetic patients show the polymicrobial nature of these lesions, which contain commensal bacteria from the skin microbiota, opportunistic pathogenic bacteria and bacteria from the environment. Among Gram-positive cocci, Staphylococcus aureus is the species most often identified in diabetic foot osteomyelitis (DFO) (23.4%), followed by Pseudomonas spp. (11.1%), Escherichia coli (11.5%), Proteus spp. (8.3%), Klebsiella spp. (6.9%), and Enterococcus spp. (5.4%). Coagulase-negative staphylococci, although involved in less than 4% of infections, often remain difficult to identify by mass spectrometry at species level, even though some of them are known for their pathogenicity. The other major difficulty is the time it takes to obtain results when osteomyelitis is suspected. In such situations, obtaining a bone sample is the standard method and the best way to identify the pathogen(s) responsible and their sensitivity to antibiotics. Bone biopsy can be performed intraoperatively or percutaneously, as recommended by the International Working Group of the Diabetic Foot (IWGDF) in 2023. In addition, to avoid false-negative cultures, experts suggest delaying bone biopsy in patients already on antibiotics, ideally for at least two weeks. In the microbiology laboratory, the standard diagnosis based on conventional microbiological culture can take up to two weeks to identify the causative bacteria and perform antibiotic susceptibility testing on the responsible pathogen(s), bringing the total time to establish a diagnosis to 4 weeks.To reduce this delay, certain culture-free molecular microbiology techniques, in particular metagenomic next-generation sequencing (mNGS), have shown that the microbiota of most wound infections is more diverse and abundant than that revealed by conventional culture methods. However, very few metagenomic data on bone biopsies from DFOMs are available. As molecular biology tools were unable to distinguish between live and dead bacterial cells and cannot identify the bacterial genera contributing to the clinical status of the infection, their use in daily practice is not recommended by the IWGDF and SPILF (Société de Pathologie Infectieuse de Langue Française), as their results could lead to the unnecessary use of broad-spectrum antibiotics. Recent studies based on metagenomic analysis of bone biopsies, soft tissue biopsies and swabs from foot wounds in diabetic patients have identified microbial diversity as a marker of infection. The number of bacteria involved in confirmed cases of infection is estimated at over 70, a figure difficult to achieve with conventional routine methods. The use of PCR based on amplification of the gene coding for 16S rRNA is considered unsuitable due to the frequent polymicrobial nature of DFOM samples. Multiplex PCR methods are not exhaustive in identifying all pathogens. Finally, conventional culture methods are often time-consuming, and species identification using laboratory methods such as MALDI-TOF mass spectrometry is often a source of confusion or failure. Recently, a new rapid sequencing tool has been developed: the MinION. It is small and fast and can sequence a bacterial or viral genome from single-microbe samples in less than four hours, or determine a panel of microorganisms present in a more complex sample. This tool is particularly useful for cerebrospinal fluid.
1,079 studies on the registry are indexed under Diabetic Foot; 221 are open to participants now.
This study's planned enrollment of 43 is below the median of 100 across 191 observational studies indexed under Diabetic Foot.
Browse Diabetic Foot studies →Centre Hospitalier Universitaire de Nīmes is the lead sponsor of 595 studies on the registry; 87 are open to participants now.
Compared within Diabetic Foot, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Diabetes Mellitus. The counts are of registry records indexed under each term, refreshed daily. How we classify →
147 bone biopsies from 43 diabetic patients collected in the orthopedic surgery operating room
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Number of bacterial and fungal species found in a conventional bone biopsy
Number of species found by each method (presence/absence and species identification): bacterial and fungal species detected in bone biopsies by the two methods (conventional culture vs MinION
Time frame: 12 months
Number of bacterial and fungal species found with the MiniON device
Number of species found by each method (presence/absence and species identification): bacterial and fungal species detected in bone biopsies by the two methods (conventional culture vs MinION
Time frame: 12 months
Description of the bone microbiota of diabetic foot osteomyelitis using the MinION method
Typology of microbial species found using the MinION method. The MinION™ Mk1D is the next generation of portable nanopore sequencing devices. Improved thermal dissipation capabilities of the MinION Mk1D significantly enhances sequencing performance, enabling highly accurate real-time sequencing in an even wider range of environments than its predecessor, the MinION Mk1B.
Time frame: 12 months
Description of the bone microbiota of diabetic foot osteomyelitis using the conventional method (MALDI-TOF)
Typology of microbial species found using the MALDI-TOF method. The MALDI-TOF (Matrix Assisted Laser Desorption Ionization - Time of Flight) instrument is a mass spectrometer that combines a matrix-assisted laser ionization source (MALDI) with a time-of-flight analyzer (TOF). One of the important characteristics of mass spectrometry is peak sharpness, measured by the resolution of the mass spectrometer. Resolution is defined as the ratio of the peak mass m to the full width at half maximum Δm. The higher the resolution, the sharper the peaks. This makes it possible to visualize two molecules with similar masses. MALDI-TOF instruments can be equipped with a reflection (electrostatic mirror or "ion mirror") that deflects ions with an electric field, thereby doubling the length of the ion flight path and increasing the resolution of the instrument. A MALDI-TOF mass spectrometer can achieve resolutions of 5000 in linear mode (without reflection) and 20000 with reflecton.
Time frame: 12 months
New potentially pathogenic species in diabetic foot osteomyelitis in relation to wound progression.
Degree of wound healing at 3 months, 6 months and one year, depending on the presence or absence of different microbial species.
Time frame: 3 months
New potentially pathogenic species in diabetic foot osteomyelitis in relation to wound progression.
Degree of wound healing at 3 months, 6 months and one year, depending on the presence or absence of different microbial species.
Time frame: 6 months
New potentially pathogenic species in diabetic foot osteomyelitis in relation to wound progression.
Degree of wound healing at 3 months, 6 months and one year, depending on the presence or absence of different microbial species.
Time frame: 12 months
Antibiotic sensitivity profiles of microorganisms obtained in vitro (bacterial culture).
The number and % of strains resistant to antibiotics tested on pathogenic bacteria isolated in standard microbiological culture will be recorded.
Time frame: 12 months
Antibiotic sensitivity profiles of microorganisms obtained in silico (MinION technology).
Presence/absence of resistance genes to the antibiotic families tested on pathogenic bacteria isolated in standard microbiological culture
Time frame: 12 months
Cost of conventional in vitro culture and testing
Cost in Euros
Time frame: 12 months
Cost of using in silico MinION technology
Cost in Euros
Time frame: 12 months
Gender of patients providing samples
Male/female/Non-binary
Time frame: Baseline
Age of patients providing samples
In years
Time frame: Baseline
Body mass index of patients providing samples
The formula is BMI = kg/m2; kg is a person's weight in kilograms and m2 is height in meters squared
Time frame: Baseline
Wound grade
Wagner Grade 1: Partial- or full-thickness ulcer (superficial ulcer) Wagner Grade 2: Deep ulcer extended to ligament, tendon, joint capsule, bone, or deep fascia without abscess or osteomyelitis (OM) Wagner Grade 3: Deep abscess, OM, or joint sepsis. Wagner Grade 4: Partial-foot gangrene.
Time frame: Baseline
Previous antibiotherapy
YES/NO
Time frame: Baseline
Evolution of the wound at 3 months
Healed/Worsening
Time frame: Month 3
Evolution of the wound at 6 months
Healed/Worsening
Time frame: Month 6
Evolution of the wound at 12 months
Healed/Worsening
Time frame: Month 12
Started Feb 2026 (actual). Primary completion is estimated for Jun 2027, 16 months after the start.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 13, 2026: start Jan 2026 → Feb 2026, primary completion Jun 2026 → Jun 2027 and completion Dec 2026 → Dec 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Centre Hospitalier Universitaire de Nīmes →